WVE - Wave Life Sciences

-

$undefined

N/A

(N/A)

Wave Life Sciences NasdaqGM:WVE Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Location: Marina One East Tower, Singapore, 018936, Singapore | Website: https://wavelifesciences.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

764.1M

Cash

243.1M

Avg Qtr Burn

-45.16M

Short % of Float

19.59%

Insider Ownership

16.35%

Institutional Own.

85.15%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
WVE-N531 Details
Duchenne muscular dystrophy

NDA

Submission

WVE-003 Details
Huntington's disease

Phase 2/3

Initiation

Phase 2

Data readout

WVE-006 Details
Alpha-1 Antitrypsin Deficiency

Phase 1/2

Data readout

WVE-120101 (SNP1) Details
Huntington's disease

Failed

Discontinued

WVE-004 Details
Amyotrophic lateral sclerosis, Frontotemporal dementia with GRN mutations

Failed

Discontinued

WVE-120102 (SNP2) Details
Huntington's disease

Failed

Discontinued